CRISPR–Cas13 Precision Transcriptome Engineering in Cancer
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated genes (Cas) system has been rapidly harnessed to perform various genomic engineering tasks. Recently, it has been demonstrated that a novel RNA-targeting CRISPR effector protein, called Cas13, binds and cleaves RNA rather than DNA substrates analogously to the eukaryotic RNA interference system. The known Cas13a–Cas13d effectors are able to efficiently cleave complementary target single-stranded RNAs, which represent a potentially safer alternative to deoxyribonuclease Cas9, because it induces loss-of-function phenotypes without genomic loss of the targeted gene. Furthermore, through the improvement in Cas13 effector functionalities, a system called REPAIR has been developed to edit full-length transcripts containing pathogenic mutations, thus providing a promising opportunity for precise base editing. Moreover, advanced engineering of this CRISPR effector also permits nucleic acid detection, allowing the identification of mutations in cell-free tumor DNA through a platform termed Specific High Sensitivity Enzymatic Reporter Unlocking. All of these properties give us a glimpse about the potential of the CRISPR toolkit for precise transcriptome engineering, possibly leading to an expansion of CRISPR technologies for cancer therapeutics and diagnostics. Here, we examine previously unaddressed aspects of the CRISPR-based RNA-targeting approach as a feasible strategy for globally interrogating gene function in cancer in a programmable manner. Cancer Res; 78(15); 4107–13. ©2018 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Genetic screens in human cells using the CRISPR-Cas9 system
Wang, T., Wei, J. J., Sabatini, D. M., & Lander, E. S. (2014) · Science · doi:10.1126/science.1246981 · Cited by 2,856 · cited 1×
“Thus, by taking advantage of the endogenous DNA repairmachinery of the cell (nonhomologous end joiningor homology directed repair) and by its ease of design and high targeting efficiency, the CRISPR/Cas9 system has rapidly evolved into a gene-editing tool in a wide range of organisms, as well as an in vivo and in vitr…”
BackgroundRNA targeting with CRISPR–Cas13
Abudayyeh, O. O., Gootenberg, J. S., Essletzbichler, P., Han, S., Joung, J., Belanto, J. J., Verdine, V., Cox, D. B. T., Kellner, M. J., Regev, A., et al. (2017) · Nature · doi:10.1038/nature24049 · Cited by 2,093 · cited 9×
“This knockdown event was abolished by mutating the catalytic domain of LwaCas13a (26).”
BackgroundMethodInfluentialDiversity, classification and evolution of CRISPR-Cas systems
Koonin, E. V., Makarova, K. S., & Zhang, F. (2017) · Current Opinion in Microbiology · doi:10.1016/j.mib.2017.05.008 · Cited by 1,423 · cited 1×
“Although the most widely known Class 2 Type II system is characterized by a single-component effector protein, Cas9, the putative Class 2 Type VI system, consists of a singleeffector protein Cas13 showing features not present in any known CRISPR protein (17, 18).”
BackgroundTranscriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors
Konermann, S., Lotfy, P., Brideau, N. J., Oki, J., Shokhirev, M. N., & Hsu, P. D. (2018) · Cell · doi:10.1016/j.cell.2018.02.033 · Cited by 1,164
Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9
Paquet, D., Kwart, D., Chen, A., Sproul, A., Jacob, S., Teo, S., Olsen, K. M., Gregg, A., Noggle, S., & Tessier-Lavigne, M. (2016) · Nature · doi:10.1038/nature17664 · Cited by 951 · cited 1×
“These versatile technologies have been repurposed to inactivate human disease-associated genes or potentially to the wild-type state, showing their enormous potential as both diagnostic and therapeutic tools in several aspects of cancer medicine (2, 3).”
BackgroundCRISPR-Cas Systems in Bacteria and Archaea: Versatile Small RNAs for Adaptive Defense and Regulation
Bhaya, D., Davison, M., & Barrangou, R. (2011) · Annual Review of Genetics · doi:10.1146/annurev-genet-110410-132430 · Cited by 914 · cited 1×
“Nearly all archaea and about one half of bacteria possess CRISPR–Cas systems, which confer immunity against viruses and other foreign DNA (4).”
BackgroundYin, H., Song, C.-Q., Dorkin, J. R., Zhu, L. J., Li, Y., Wu, Q., Park, A., Yang, J., Suresh, S., Bizhanova, A., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3471 · Cited by 876
Smargon, A. A., Cox, D. B. T., Pyzocha, N. K., Zheng, K., Slaymaker, I. M., Gootenberg, J. S., Abudayyeh, O. A., Essletzbichler, P., Shmakov, S., Makarova, K. S., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2016.12.023 · Cited by 575
Cited by
The biogenesis, biology and characterization of circular RNAs
Kristensen, L. S., Andersen, M. S., Stagsted, L. V. W., Ebbesen, K. K., Hansen, T. B., & Kjems, J. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0158-7 · Cited by 4,823
Alternative splicing and cancer: a systematic review
Zhang, Y., Qian, J., Gu, C., & Yang, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00486-7 · Cited by 497
Xu, Y., & Li, Z. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.08.031 · Cited by 404
Advances in CRISPR-Cas systems for RNA targeting, tracking and editing
Wang, F., Wang, L., Zou, X., Duan, S., Li, Z., Deng, Z., Luo, J., Lee, S. Y., & Chen, S. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.03.016 · Cited by 128
Chemically modified guide RNAs enhance CRISPR-Cas13 knockdown in human cells
Méndez-Mancilla, A., Wessels, H.-H., Legut, M., Kadina, A., Mabuchi, M., Walker, J., Robb, G. B., Holden, K., & Sanjana, N. E. (2022) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.07.011 · Cited by 68
Metadata
- Authors
- Granados-Riveron, J. T., & Aquino-Jarquin, G.
- Venue
- Cancer Research
- Published
- 2018-07-31
- Volume
- 78
- Issue
- 15
- Pages
- 4107-4113
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2883678168
- Cited by
- 90
- References
- 10
- FWCI
- 2.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CRISPR–Cas13 Precision Transcriptome Engineering in Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-18-0785
- The paper
- Granados-Riveron, J. T., & Aquino-Jarquin, G. (2018). CRISPR–Cas13 Precision Transcriptome Engineering in Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-18-0785
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.